Span Divergent Limited outcome of Board Meeting held on 10.02.2026
Awaiting price reaction for this filing.
The Board of Span Divergent Limited approved unaudited standalone and consolidated financial results for Q3 FY26 (quarter ended Dec 31, 2025) and the nine-month period. On a standalone basis, total income fell to Rs 53.73 lakhs from Rs 64.44 lakhs in Q3 FY25, and PAT dropped to Rs 13.74 lakhs (EPS Rs 0.25) from Rs 23.49 lakhs (EPS Rs 0.43). Consolidated revenue, however, grew sharply to Rs 406.54 lakhs in Q3 (vs Rs 232.61 lakhs) and Rs 1,372.02 lakhs for 9M (vs Rs 926.43 lakhs), but consolidated loss after tax widened to Rs 113.66 lakhs in Q3 and Rs 149.44 lakhs for 9M, with reserves turning negative at Rs (826.86) lakhs. Exceptional items of Rs 14.20 lakhs in Q3 (Rs 33.50 lakhs for 9M) were booked. Several subsidiaries - including Biospan Contamination Control Solutions (negative net worth of Rs 6.81 crores) and Aranya Agri Biotech (accumulated losses of Rs 15.12 crores) - are being carried on a going-concern basis. The auditor issued an unmodified review report.
Shareholders should note the stark divergence between the standalone picture (modest profit, declining) and the consolidated picture (revenue growth but widening losses and negative reserves), driven by loss-making subsidiaries in cashew processing and trading. The going-concern dependency on subsidiary revival plans and accumulated losses raise execution risk for investors.